RougeTx
PrivateLast Round
Series A
Oct 6, 2026
Total Funding Raised
$58M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
RougeTx is a biotechnology company developing first-in-class small-molecule therapies to restore vascular stability in diseases driven by pericyte dysfunction.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RougeTx Comparables
Compare RougeTx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Scenic Biotech | 83% | |
| Azafaros | 80% | |
| Vaderis Therapeutics | 79% |
RougeTx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Oct 6, 2026 |
RougeTx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Epidarex Capital | Series A |
| ROM Utrecht Region | Series A |
| European Investment Bank Group | Series A |
| Vesalius Biocapital Partners | Series A |
| Angelini Ventures | Series A |
| P53 Invest | Series A |
| BioGeneration Ventures | Seed, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 6, 2026
$58M round with participation from BioGeneration Ventures and Epidarex Capital.
Recent news
Latest coverage and updates
- is_developingOct 6, 2026
RougeTx plans to further develop RTX-001 toward first human clinical trials in the Netherlands on Oct 7th '26
- hiresOct 6, 2026
RougeTx will add Regina Hodits, Managing Director of Angelini Ventures, to its Board of Directors
- receives_financingOct 6, 2026
RougeTx launched with a $58M Series A financing co-led by BioGeneration Ventures, Angelini Ventures, and Kurma Partners, with participation from EIB co-investment facility Aurea and other investors, to advance RTX-001 toward first-in-human development for hereditary hemorrhagic telangiectasia in the Netherlands on Oct 6th '26.
- hiresOct 6, 2026
RougeTx will add Elizabeth Roper, Managing Partner at Epidarex Capital, to its Board of Directors alongside existing directors in connection with the financing on Oct 6th '26.
- hiresOct 6, 2026
In connection with the financing, RougeTx will add Hadrien Bouchez, a Partner at Kurma Partners, to its Board of Directors alongside existing directors on Oct 6th '26.
RougeTx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about RougeTx's valuation, stock price, and market status.
Is RougeTx a public or private company?
RougeTx is a private company.
What is the current stock price of RougeTx?
RougeTx is a private company, so its shares have no public market price. Caplight tracks RougeTx's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is RougeTx worth (valuation)?
Valuation information for RougeTx is not publicly available.
Can I buy RougeTx stock?
RougeTx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was RougeTx's last funding round?
RougeTx's most recent funding round was Series A on October 6, 2026.
Who are the main investors in RougeTx?
Key investors in RougeTx include BioGeneration Ventures.
Will RougeTx IPO soon?
No public IPO plans have been announced for RougeTx.
How can I track RougeTx secondary market activity?
Caplight tracks bids, offers, and trades in RougeTx's shares on secondary markets.